Sodium Polystyrene Sulfonate

CHEMBL1201484 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Taken orally or as an enema, this resin medication passes through the gut without being absorbed and binds to excess potassium in the intestine, which is then removed from the body in the stool. It is used in kidney disease and heart failure to manage dangerously elevated potassium levels that could otherwise trigger life-threatening heart arrhythmias.

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Taken orally or as an enema, this resin medication passes through the gut without being absorbed and binds to excess potassium in the intestine, which is then removed from the body in the stool. It is used in kidney disease and heart failure to manage dangerously elevated potassium levels that could otherwise trigger life-threatening heart arrhythmias.

Yes, Sodium Polystyrene Sulfonate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201484. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.